FDA OKs First IL-15 Receptor Agonist for Early Bladder Cancer
(MedPage Today) -- The FDA approved nogapendekin alfa inbakicept (Anktiva) for bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), the agency announced Monday.
A first-in-class interleukin (IL)-15 receptor...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Bladder Cancer | Cancer | Cancer & Oncology | International Medicine & Public Health